SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2.70 |
| Enterprise Value ($M) | 2.70 |
| Book Value ($M) | 0.00 |
| Book Value / Share | 0.00 |
| Price / Book | n/a |
| NCAV ($M) | 0.00 |
| NCAV / Share | 0.00 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | n/a |
| Current Ratio | n/a |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.00 |
| Assets | 0.00 |
| Liabilities | 0.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Lui Darren | 14.50 | 18.64 | |
| 13G/A | Hudson Bay Capital Management LP | 3.05 | -90.03 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 10,817 | 26,568 | 40.71 | |
| 2,749 | 25,775 | 10.67 | |
| 9,943 | 61,172 | 16.25 | |
| 33,524 | 144,067 | 23.27 | |
| 65,166 | 291,211 | 22.38 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALZN – Alzamend Neuro, Inc. | ANEB – Anebulo Pharmaceuticals, Inc. |
| ANIX – Anixa Biosciences, Inc. | APRE – Aprea Therapeutics, Inc. |
| APTO – Aptose Biosciences Inc. |
Financial data and stock pages provided by
Fintel.io